계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Acorda Therapeutics
About
Acorda Therapeutics began in 1995 as a network of scientists, physicians and business people with a common belief.
- 251 - 500
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $55.30M
- Industries
- Biotechnology,Developer Platform,Health Care
- Founded date
- Jan 1, 1995
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 20, 2003 | Series B | $55.30M | 1 | — | — | Detail |
| Jan 8, 2001 | Series A | $33.70M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Cross Atlantic Partners
|
— | Series B |
BayStar Capital
|
— | Series A |
